Sorrento Therapeutics Inc
Change company Symbol lookup
Select an option...
SRNEQ Sorrento Therapeutics Inc
SPI SPI Energy Co Ltd
AMC AMC Entertainment Holdings Inc
BOF BranchOut Food Inc
KITT Nauticus Robotics Inc
EAT Brinker International Inc
JCSE JE Cleantech Holdings Ltd
GVP GSE Systems Inc
CURV Torrid Holdings Inc
APRN Blue Apron Holdings Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Closing Price
Day's Change
-0.0062 (-6.19%)
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

Coinbase's stock sinks again as penalties from SEC suit could top $6 billion, analyst says

3:38 pm ET June 6, 2023 (MarketWatch)

By Tomi Kilgore

SEC suit against the crypto exchange was in line with expectations, but penalties could a lot worse than feared

Shares of Coinbase Global Inc. tumbled again Tuesday, amid worries that the fallout from regulatory actions could be a lot worse than previously feared.

On Tuesday, U.S. Securities and Exchange Commission (SEC) said that it charged the cryptocurrency exchange with illegally offering exchange, brokerage, clearing and staking services. The suit came a day after the SEC charged rival Binance Holdings Inc. with securities fraud.

Barclays analyst Benjamin Budish said the SEC's suit against Coinbase is largely consistent with his expectations, and with what the SEC warned the company about in March. But there's more.

"[I]n the suit, the SEC also orders Coinbase to 'disgorge... all ill-gotten gains' resulting from the alleged violations, with interest -- in other words, the company would be required to pay a penalty totaling the entirety of revenues generated from trading in digital asset securities," Budish wrote in a note to clients.

Based on his analysis, Budish said Coinbase could be on the hook for a penalty of just over $6 billion, which would be "quite meaningful versus our prior expectations."

Budish reiterated his equal weight rating on the stock and his $61 price target.

The stock (COIN) dove as much as 20.9% intraday, before paring some losses to be down 12.0% in afternoon trading, and after sinking 9.1% on Monday.

The combined 20.0% selloff would be the stock's worst two-day performance since it plunged 21.1% over the two days ending March 23, after Coinbase received the SEC's warning. The difference is, the stock was recently trading about 22% below where it closed on March 23.

Coinbase Chief Executive Officer Brian Armstrong responded by tweeting, "we're proud to represent the industry in court to finally get some clarity around crypto rules."

In addition to the SEC's suit, the Alabama Securities Commission (ASC) issued a "Show Order" to Coinbase, giving the company 28 days to "show cause why they should not be directed to cease and desist from selling unregistered securities in Alabama."

The ASC said its action is a result of a task force made up of securities regulators of 10 cents, including Alabama, California, Illinois, Kentucky, Maryland, New Jersey, South Carolina, Vermont, Washington and Wisconsin.

Barclays' Budish said the ASC's order appeared to specify that the potential cease-and-desist order would apply only to Alabama.

Meanwhile, other crypto stocks bucked the weakness in Coinbase shares by bouncing sharply into positive territory. Marathon Digital Holdings Inc.'s stock (MARA) had been down as much as 7.8% intraday, but reversed course to be up 9.7% in afternoon trading, while Riot Platforms Inc. shares (RIOT) reversed an earlier loss of as much as 9.2% to trade up 2.4%.

And the price of bitcoin rose 4.3% to $26,878, reversing an earlier selloff of as much as 1.7%.

For Coinbase's stock to fall on a day bitcoin rises is rare, as the correlation coefficient between the two since Coinbase went public on April 14, 2021 was 0.93, according to a MarketWatch calculation of FactSet data. A correlation coefficient of 1.00 means two securities move exactly in tandem.

Coinbase's stock has still run up 46.0% year to date, while bitcoin has soared 61.9% and the S&P 500 index has advanced 11.6%.

-Tomi Kilgore

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

June 06, 2023 15:38 ET (19:38 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.